Interleukin-10 Polymorphisms in Association with Prognosis in Patients with B-Cell Lymphoma Treated by R-CHOP.
Interleukin-10 (IL10) plays an important role in initiating and maintaining an appropriate immune response to non-Hodgkin lymphoma (NHL). Previous studies have revealed that the transcription ofIL10mRNA and its protein expression may be infl uenced by several single-nucleotide polymorphisms in the promoter and intron regions, including rs1800896, rs1800871, and rs1800872. However, the impact of polymorphisms of theIL10gene on NHL prognosis has not been fully elucidated. Here, we investigated the association betweenIL10polymorphisms and NHL prognosis. This study involved 112 NHL patients treated at the National Cancer Center, Korea. The median age was 57 years, and 70 patients (62.5%) were men. Clinical characteristics, including age, performance status, stage, and extra-nodal involvement, as well as cell lineage and International Prognostic Index (IPI), were evaluated. A total of four polymorphisms inIL10with heterozygous alleles were analyzed for hazard ratios of overall survival (OS) and progression-free survival (PFS) using Cox proportional hazards regression analysis. Diffuse large B-cell lymphoma was the most common histologic type (n = 83), followed by T-cell lymphoma (n = 18), mantle cell lymphoma (n = 6), and others (n = 5). Cell lineage, IPI, and extra-nodal involvement were predictors of prognosis. In the additive genetic model results for eachIL10polymorphism, the rs1800871 and rs1800872 polymorphisms represented a marginal association with OS (p = 0.09 and p = 0.06) and PFS (p = 0.05 and p = 0.08) in B-cell lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). These findings suggest thatIL10polymorphisms might be prognostic indicators for patients with B-cell NHL treated with R-CHOP.
Department of System Cancer Science, Graduate School of Cancer Science and Policy, Goyang 10408, Korea.
Min Kyeong
MK
Kim
Center for Breast Cancer, National Cancer Center, Goyang 10408, Korea.; College of Veterinary Medicine, Konkuk University, Seoul 05029, Korea.
Kyong-Ah
KA
Yoon
Biometric Research Branch, Division of Cancer Epidemiology and Prevention, National Cancer Center, Goyang 10408, Korea.
Eun Young
EY
Park
Biometric Research Branch, Division of Cancer Epidemiology and Prevention, National Cancer Center, Goyang 10408, Korea.
Jungnam
J
Joo
Center for Hematologic Malignancy, National Cancer Center, Goyang 10408, Korea.
Eun Young
EY
Lee
Center for Hematologic Malignancy, National Cancer Center, Goyang 10408, Korea.
Hyeon-Seok
HS
Eom
Department of System Cancer Science, Graduate School of Cancer Science and Policy, Goyang 10408, Korea.; Center for Hematologic Malignancy, National Cancer Center, Goyang 10408, Korea.; Department of Laboratory Medicine, Center for Diagnostic Oncology, Research Institute and Hospital, National Cancer Center, Goyang 10408, Korea.
Sun-Young
SY
Kong
interleukin-10; non-Hodgkin lymphoma; prognosis; single nucleotide polymorphism